Table 5.

Clinical and laboratory characteristics of GO patients before and after treatment (n = 32).

	Before treatment	After treatment	P Vaule
CAS	3.50(2.62–4.00)	2.00(2.00–2.88)	< 0.001***
FT3(pg/ml)	3.57(2.89–4.98)	3.19(2.90–3.70)	0.178
FT4 (ng/dl)	1.33(0.84–1.81)	1.32(1.16–1.53)	0.807
TSH (IU/ml)	0.075(0.006–3.210)	1.630(0.390–2.883)	0.262
TPOAb(IU/ml)	18.40(5.65–70.68)	15.70(4.50–33.40)	0.004**
TGAb(IU/ml)	16.85(14.85–29.50)	16.80(14.10–22.30)	0.016*
TRAb(U/L)	7.50(3.53–21.78)	2.66(1.36–8.76)	< 0.001***
IgG (g/L)	10.75(9.36–12.30)	9.48(8.92–10.80)	< 0.001***
IgG4 (g/L)	1.10(0.56–2.18)	0.92(0.46–1.69)	0.583
IgG4/IgG(%)	9.83(5.54–16.33)	9.76(4.72–20.55)	0.295
IL-2 (pg/ml)	1.27 ± 0.42	1.17 ± 0.33	0.228
IFN-γ(pg/ml)	0.82(0.23–1.46)	0.98(0.05–1.91)	0.336
IL-5(pg/ml)	1.21(0.92–2.73)	1.41(0.88–3.45)	0.266
IL-6(pg/ml)	1.97(1.35–3.25)	1.69(0.81–2.54)	0.130
IL-10 (pg/ml)	1.16(0.88–1.57)	1.15(0.85–1.64)	0.851
IL-17 (pg/ml)	0.81(0.16–1.64)	0.78(0.37–1.54)	0.612
Eosinophil count(10^9/L)	0.10(0.07–0.16)	0.09(0.06–0.13)	0.275
Percentage of eosinophils(%)	2.00(1.20–3.20)	1.30(0.80–2.40)	< 0.001***